Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05781321 · ClinicalTrials.gov registry record · Phase 2

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

A Phase 2 study of Glioblastoma, sponsored by Mayo Clinic.

Active
Registry status
Phase 2
Development phase
170
Enrollment target
8
Study locations

NCT05781321: Active Phase 2 study of Glioblastoma, sponsored by Mayo Clinic.

NCT05781321 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 170 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (57% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05781321, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
170 participants
Enrollment target
8
Study locations

Study Summary

This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.

Conditions Studied

Glioblastoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Positron Emission Tomography
  • DRUG Fluorodopa F 18
  • RADIATION Accelerated Hypofractionated Radiation Therapy

Study Locations (8)

Minnesota

  • Mayo Clinic Health System in Albert Lea - Albert Lea
  • Mayo Clinic Health Systems-Mankato - Mankato
  • Mayo Clinic Radiation Therapy - Northfield - Northfield
  • Mayo Clinic in Rochester - Rochester

Wisconsin

  • Mayo Clinic Health System-Eau Claire - Eau Claire
  • Mayo Clinic Health System-Franciscan Healthcare - La Crosse

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2023-03-23
Est. Completion 2028-07-02
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05781321

The ClinicalTrials.gov registry entry for NCT05781321 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (57% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT05781321 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Wisconsin, Arizona.

Frequently Asked Questions

What is clinical trial NCT05781321 about?

NCT05781321 is a clinical study titled "Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study". This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with...

What is the current status of trial NCT05781321?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2023-03-23. Estimated completion is 2028-07-02.

What conditions does trial NCT05781321 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT05781321?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fluorodopa F 18 (DRUG), Accelerated Hypofractionated Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT05781321?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05781321 being conducted?

This trial has 8 study locations across Arizona, Florida, Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.